In brief

• The Kierunek Zdrowie Association is calling for wider use of time-limited therapy for chronic lymphocytic leukemia.
• According to the association's president, Dominik Romiński, this model could help patients, especially younger ones, plan their return to work.
• The solution would apply to patients covered by the drug program.

The proposal for chronic lymphocytic leukemia

Dominik Romiński, President of the Management Board of the Kierunek Zdrowie Association, said on the sidelines of the Forum Rynku Zdrowia that the organization hopes for a systemic solution concerning the course of chronic lymphocytic leukemia. The aim is wider use of therapies that have a predetermined duration (Rozwiązania dla chorych ze szpiczakiem i przewlekłą białaczką limfocytową – GazetaPrawna.pl).

Benefits for patients and the payer

According to Romiński, such a model is economically advantageous within a specific drug program. It also gives patients clarity about when treatment will end.

This is particularly important for younger patients. Knowing the end date of therapy, they can plan the moment of their return to professional work. The president stressed that the labor market currently has a great need for such competencies and that they should not go to waste.

Who the solution is for

The solution concerns patients with chronic lymphocytic leukemia whose treatment is covered by a drug program. The Association's conclusions therefore apply primarily to this group of patients and their return to professional activity.

The matter fits into a broader discussion about how blood cancers are treated in Poland, held at an industry forum where representatives of patients, the payer, and the medical world meet.